A prospective, randomised, open, crossover patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients
| ISRCTN | ISRCTN03265047 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN03265047 |
| Protocol serial number | 2006-001-Oxy-OAB-Skin-Oxy |
| Sponsor | Johannes Gutenberg-Universität Mainz, Fachbereich Medizin (Germany) |
| Funder | UCB Farchim S.A. (Switzerland) |
- Submission date
- 31/01/2007
- Registration date
- 22/03/2007
- Last edited
- 30/07/2009
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Urological and Genital Diseases
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Johannes Gutenberg-Universität Mainz
Department of Urology
Langenbeckstr. 1
Mainz
55131
Germany
| Phone | +49 (0)6131-17-2310 |
|---|---|
| hampel@urologie.klinik.uni-mainz.de |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective, randomised, open, 2 x 6 - week crossover, single-centre subject preference trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study acronym | Oxy-OAB-Skin-Oxy |
| Study objectives | The primary endpoint is treatment preference of subjects who will be asked at the end of the 2nd treatment period. The preference will be checked for its plausibility in an end-of-period satisfaction rating (6 = very satisfied, 0 = very dissatisfied). Treatment satisfaction will be assessed at the end of each period of the cross over. The total score on the satisfaction visual analog scale of the two treatment periods will be compared to express preference. |
| Ethics approval(s) | In progress as of 2 February 2007 |
| Health condition(s) or problem(s) studied | Subjects with overactive bladder (OAB) |
| Intervention | As of 29/07/09 the status of this trial was updated to 'stopped' due to poor recruitment. The decsion to terminate the trial was made on 25/11/2008, the date of last patient out (LPO) was on 17/07/2009 Test product: Kentera™ TDS 3,9 mg/24h, transdermal patch vs Reference therapy: Oxybutynin ratiopharm® 5 mg, tablets |
| Intervention type | Other |
| Primary outcome measure(s) |
Primary efficacy endpoint will be the personal preference of the subject after both treatment phases. The preference will be checked for its plausibility in an end-of-period satisfaction rating (total of scores of final list of questions: 6 = very satisfied, 0 = very dissatisfied) |
| Key secondary outcome measure(s) |
1. Cognitive abilities during treatment with orally administered Oxybutynin versus transdermal administration of Oxybutynin measured by CNS tests (Trail Making Test and Wechsler Memorial Scale-Revised) |
| Completion date | 01/12/2007 |
| Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 80 |
| Key inclusion criteria | Subjects meeting all of the following criteria will be considered for admission to the trial: 1. Male or female (18 80 years) suffering from OverActive Bladder (OAB) 2. Symptoms of OAB as defined by: a. Urgency frequency ≥7 /week b. Urinary urgency incontinence (> 7 UIE/week) c. Urodynamically proven detrusor instability 3. Women must be surgically sterile, be postmenopausal or must agree to use effective contraception during treatment phases (i.e. contraceptions with a failure ratio of < 1%/ year are implants, injection preparations, combined oral contraceptives, intrauterine device [e.g. hormone spiral] or vasectomy of the partner) 4. Negative urine pregnancy test for women capable of child-bearing within 24 hours before administration of the first dose medication at V1 5. Signed and dated informed consent of the subject must be available before start of any specific trial procedures 6. Ability of subject to understand character and individual consequences of clinical trial |
| Key exclusion criteria | Subjects presenting with any of the following criteria will not be included in the trial: 1. Pregnancy and lactation 2. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product 3. Subjects with significant urinary obstruction as measured during cystometry (e.g. prostatic hyperplasia, stricture of urethra), severe gastro-intestinal condition (e.g. toxic megacolon, severe ulcerative colitis, intestinal atony, bowel obstruction), myasthenia gravis or uncontrolled narrow-angle glaucoma 4. Refractory to antimuscarine treatment: Subjects having experienced no benefit from previous treatment with oral or transdermal oxybutynin 5. Subjects with hiatus hernia and reflux oesophagitis 6. Subjects with acute prostatitis 7. Subjects with urinary frequency or nocturia due to cardiac or renal insufficiency and without urgency 8. Subjects with tachyarrhythmia (pulse > 100/min) 9. Subjects with Parkinsons`s disease or Alzheimer`s disease or other cerebral diseases 10. Subjects with cognitive impairment, not able to understand content and aim of the trial 11. Medical or psychological condition that would not permit completion of the trial or signing of informed consent 12. Participation in other clinical trials and observation period of competing trials, respectively 13. Subjects who have previously been enrolled in the trial |
| Date of first enrolment | 01/03/2007 |
| Date of final enrolment | 01/12/2007 |
Locations
Countries of recruitment
- Germany
Study participating centre
55131
Germany
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
